CW
Therapeutic Areas
MEKanistic Therapeutics Pipeline
| Drug | Indication | Phase |
|---|---|---|
| MTX-531 | PIK3CA-mutant solid tumors (e.g., head and neck, breast, lung, gastrointestinal) | Preclinical |
Leadership Team at MEKanistic Therapeutics
DC
Danny Cunagin
Chief Executive Officer
JL
Judith Leopold, PhD
Chief Scientific Officer
HY
Hagop Youssoufian, MD
Chief Medical Advisor